Nat Commun: New molecular classification promotes precision treatment strategies for primary Sjogren’s syndrome

Primary Sjogren’s syndrome (pSS) is a chronic, disabling, and complex systemic autoimmune disease, which mainly affects adult women, and there is still a lack of effective targeted treatment strategies
.

Primary Sjogren’s syndrome (pSS) is a chronic, disabling, and complex systemic autoimmune disease, which mainly affects adult women, and there is still a lack of effective targeted treatment strategies
.

Primary Sjogren’s syndrome (pSS) is a chronic, disabling, and complex systemic autoimmune disease, which mainly affects adult women, and there is still a lack of effective targeted treatment strategies

Although the involvement of salivary and lacrimal glands is a major sign of the disease, various organs and systems including joints, lungs, kidneys, liver, nerves, and musculoskeletal systems may be involved in the development of pSS
.

Therefore, the clinical scope of the disease ranges from benign and slowly progressing autoimmune exocrine diseases to severe systemic diseases with significant symptom heterogeneity and scattered complications

The diagnosis of pSS is currently mainly based on a combination of clinical, serological, histological and functional parameters
.

In addition, one-fifth of pSS patients may have major organ involvement and potentially severe end-organ damage, and 5% of patients may also develop non-Hodgkin’s lymphoma

The heterogeneity of the clinical manifestations and pathophysiology of the disease also makes it difficult to develop effective treatments for the disease
.

Therefore, finding common molecular characteristics in patient subgroups can improve the understanding of the etiology of the disease and promote the development of related targeted therapies

In this study, the researchers reported the relevant molecular typing scheme of Sjogren’s syndrome patients in a descriptive cohort based on multi-omics analysis of whole blood samples from a cohort of more than 300 European patients, and similar numbers Sample data of healthy volunteers matched by age and gender
.

The researchers reported on a descriptive cohort of related molecular typing schemes for patients with Sjogren’s syndrome based on a multi-omics analysis of whole blood samples from a cohort of more than 300 European patients, and a similar number of age and gender matches Sample data of healthy volunteers
.

The researchers reported on a descriptive cohort of related molecular typing schemes for patients with Sjogren’s syndrome based on a multi-omics analysis of whole blood samples from a cohort of more than 300 European patients, and a similar number of age and gender matches Sample data of healthy volunteers

Molecular typing of 4 different typical pathways in patients with pSS

Molecular typing of 4 different typical pathways in patients with pSS

Researchers used transcriptomics, genomics, epigenetics, cytokine expression and flow cytometry data, combined with relevant clinical parameters, to determine four patient subgroups (C1-C4) with different immune disorders
.

Researchers used transcriptomics, genomics, epigenetics, cytokine expression, and flow cytometry data, combined with relevant clinical parameters, to determine four patient subgroups (C1-C4) with different immune disorders
.

Researchers used transcriptomics, genomics, epigenetics, cytokine expression and flow cytometry data, combined with relevant clinical parameters, to determine four patient subgroups (C1-C4) with different immune disorders

The abundance patterns of different modules distinguish four subgroups of pSS

The abundance patterns of different modules distinguish four subgroups of pSS

All in all, the biomarkers identified in the study can be used to classify patients into subgroups through machine learning classifiers, so that patients' response to treatment can be reassessed in clinical trials
.

The biomarkers identified in the study can be used to classify patients into subgroups through machine learning classifiers, so that the patient's response to treatment can be reassessed in clinical trials
.

The biomarkers identified in the study can be used to classify patients into subgroups through machine learning classifiers, so that the patient's response to treatment can be reassessed in clinical trials

Soret, P.
, Le Dantec, C.
, Desvaux, E.
et al.
A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.
Nat Commun 12, 3523 (10 June 2021).

A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.

 

Leave a message here